Neuren Pharmaceuticals Ltd
ASX:NEU
Neuren Pharmaceuticals Ltd
ASX:NEU
Price:
12.26
AUD
2.08%
Market Closed
Market Cap:
1.6B
AUD
Balance Sheet
Balance Sheet Decomposition
Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Ltd
| Current Assets | 399.3m |
| Cash & Short-Term Investments | 222.2m |
| Receivables | 175.7m |
| Other Current Assets | 1.4m |
| Non-Current Assets | 10.4m |
| PP&E | 31k |
| Other Non-Current Assets | 10.3m |
Balance Sheet
Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Ltd
Currency: AUD
Millions
Annual
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
4
|
3
|
2
|
4
|
14
|
24
|
37
|
40
|
17
|
3
|
|
| Cash |
4
|
3
|
2
|
4
|
1
|
0
|
7
|
2
|
17
|
3
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
13
|
24
|
30
|
38
|
0
|
0
|
|
| Short-Term Investments |
12
|
2
|
3
|
20
|
0
|
0
|
0
|
0
|
211
|
219
|
|
| Total Receivables |
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
14
|
175
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
173
|
|
| Other Receivables |
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
2
|
|
| Other Current Assets |
0
|
0
|
11
|
2
|
0
|
0
|
2
|
2
|
4
|
2
|
|
| Total Current Assets |
17
|
6
|
16
|
27
|
14
|
25
|
40
|
43
|
247
|
399
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
1
|
10
|
|
| Total Assets |
17
N/A
|
6
-63%
|
18
+189%
|
27
+48%
|
14
-46%
|
25
+73%
|
40
+61%
|
43
+8%
|
248
+473%
|
410
+65%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
2
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Accrued Liabilities |
1
|
1
|
1
|
1
|
0
|
1
|
1
|
1
|
3
|
1
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
39
|
43
|
|
| Total Current Liabilities |
3
|
2
|
2
|
2
|
1
|
1
|
1
|
2
|
43
|
46
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
3
N/A
|
2
-19%
|
2
-22%
|
2
+25%
|
1
-72%
|
1
+35%
|
1
+7%
|
2
+109%
|
43
+2 448%
|
46
+7%
|
|
| Equity | |||||||||||
| Common Stock |
112
|
113
|
121
|
126
|
126
|
146
|
168
|
168
|
173
|
165
|
|
| Retained Earnings |
87
|
98
|
94
|
91
|
102
|
111
|
118
|
115
|
43
|
185
|
|
| Other Equity |
11
|
11
|
11
|
11
|
11
|
11
|
11
|
11
|
11
|
14
|
|
| Total Equity |
14
N/A
|
4
-71%
|
16
+291%
|
25
+51%
|
14
-44%
|
24
+75%
|
39
+62%
|
42
+6%
|
205
+393%
|
364
+77%
|
|
| Total Liabilities & Equity |
17
N/A
|
6
-63%
|
18
+189%
|
27
+48%
|
14
-46%
|
25
+73%
|
40
+61%
|
43
+8%
|
248
+473%
|
410
+65%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
88
|
92
|
102
|
103
|
100
|
115
|
126
|
123
|
127
|
127
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
